|
Editorial
Acta Pharmacologica Sinica 2007 September; 28 (9): 1261
Special issue on "molecular targets, biomarkers and animal models for
anti-cancer pharmacological research: potentials and challenges from
chemoprevention to chemotherapeutic treatment"
Ah-Ng Tony KONG1
Center for Cancer Prevention Research, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New
Jersey 08854, USA
|
1 Correspondence to Prof Ah-Ng Tony
KONG. Phn 1-732-444-3831 ext 228. Fax 1-732-445-3134. E-mail KongT@rci.rutgers.edu
Received 2007-07-25; Accepted 2007-07-25
doi: 10.1111/j.1745-7254.2007.00699.x
|
|
Abstract
Key words
cancer chemoprevention; dietary food factors; natural phytochemicals; molecular targets; biomarkers; animal models
|
Extract
Note: Please read the complete
full text with Figures and Tables at
With the current advances in the field of cancer research particularly in cancer chemoprevention, we have much to
celebrate but we also have a lot of challenges before us. Some of the challenges include finding appropriate animal models for
predicting efficacy of chemopreventive compounds for human cancers, of which are usually highly complex and involved
multiple genes in nature and translating our basic research into clinical practice. One of the other challenges will be to
disseminate our ideas into the larger biomedical and pharmaceutical community. With this in mind, I have been asked by the
Editorial Team of Acta Pharmacologica
Sinica to organize a special issue to discuss the current advances in cancer
chemoprevention from prevention to treatment. The distinction and the potential overlapping nature of cancer chemoprevention
versus chemotherapeutic treatment has become somewhat blurred, since prevention of carcinogenesis encompasses
preventing any or all of the three stages of carcinogenesis namely initiation, promotion and progression. Oftentimes, many
cancer chemopreventive compounds can possess all three biological properties that culminate in the overall protection
against cancer. To be most effective, cancer chemoprevention of earlier lesions will be the ultimate goal if we are to eradicate
this dreadful disease, since advanced metastasized cancers are almost lethal and unresponsive to radiation and chemotherapy.
The reviews covered in this special issue, which are based on strong preclinical studies, will hopefully provide the impetus
to translate this information to clinical practice and improved patient care.
|
|
